Advanced drug delivery reviews最新文献

{"title":"Cell membrane-coated nanoparticles for targeting carcinogenic bacteria","authors":"Lei Sun,&nbsp;Dan Wang,&nbsp;Kailin Feng,&nbsp;Jiayuan Alex Zhang,&nbsp;Weiwei Gao,&nbsp;Liangfang Zhang","doi":"10.1016/j.addr.2024.115320","DOIUrl":"https://doi.org/10.1016/j.addr.2024.115320","url":null,"abstract":"<div><p>The etiology of cancers is multifactorial, with certain bacteria established as contributors to carcinogenesis. As the understanding of carcinogenic bacteria deepens, interest in cancer treatment through bacterial eradication is growing. Among emerging antibacterial platforms, cell membrane-coated nanoparticles (CNPs), constructed by enveloping synthetic substrates with natural cell membranes, exhibit significant promise in overcoming challenges encountered by traditional antibiotics. This article reviews recent advancements in developing CNPs for targeting carcinogenic bacteria. It first summarizes the mechanisms of carcinogenic bacteria and the status of cancer treatment through bacterial eradication. Then, it reviews engineering strategies for developing highly functional and multitasking CNPs and examines the emerging applications of CNPs in combating carcinogenic bacteria. These applications include neutralizing virulence factors to enhance bacterial eradication, exploiting bacterium-host binding for precise antibiotic delivery, and modulating antibacterial immunity to inhibit bacterial growth. Overall, this article aims to inspire technological innovations in developing CNPs for effective cancer treatment through oncogenic bacterial targeting.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115320"},"PeriodicalIF":16.1,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140639373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine","authors":"Sabina Pozzi ,&nbsp;Ronit Satchi-Fainaro","doi":"10.1016/j.addr.2024.115318","DOIUrl":"10.1016/j.addr.2024.115318","url":null,"abstract":"<div><p>The communication between cells and their microenvironment represents an intrinsic and essential attribute that takes place in several biological processes, including tissue homeostasis and tissue repair. Among these interactions, inflammation is certainly a central biological response that occurs through cytokines and the crosstalk with their respective receptors. In particular, the interaction between CCL2 and its main receptor, CCR2, plays a pivotal role in both harmful and protective inflammatory states, including cancer-mediated inflammation. The activation of the CCL2/CCR2 axis was shown to dictate the migration of macrophages with immune-suppressive phenotype and to aggravate the progression of different cancer types. In addition, this interaction mediates metastasis formation, further limiting the potential therapeutic outcome of anti-cancer drugs. Attempts to inhibit pharmacologically the CCL2/CCR2 axis have yet to show its anti-cancer efficacy as a single agent, but it sheds light on its role as a powerful tool to selectively alleviate pro-tumorigenic and anti-repair inflammation. In this review, we will elucidate the role of CCL2/CCR2 axis in promoting cancer inflammation by activating the host pro-tumorigenic phenotype. Moreover, we will provide some insight into the potential therapeutic benefit of targeting the CCL2/CCR2 axis for cancer and inflammation using novel delivery systems, aiming to sensitize non-responders to currently approved immunotherapies and offer new combinatory approaches.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115318"},"PeriodicalIF":16.1,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140776066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fusobacterium nucleatum carcinogenesis and drug delivery interventions","authors":"Zhenzhen Chen,&nbsp;Leaf Huang","doi":"10.1016/j.addr.2024.115319","DOIUrl":"10.1016/j.addr.2024.115319","url":null,"abstract":"<div><p>The microbiome has emerged as a significant biomarker and modulator in cancer development and treatment response. Recent research highlights the notable role of <em>Fusobacterium nucleatum</em> (<em>F. nucleatum</em>) in various tumor types, including breast, colorectal, esophageal, gastric, pancreatic, and lung cancers. Accumulating evidence suggests that the local microbial community forms an integral component of the tumor microenvironment, with bacterial communities within tumors displaying specificity to tumor types. Mechanistic investigations indicate that tumor-associated microbiota can directly influence tumor initiation, progression, and responses to chemotherapy or immunotherapy. This article presents a comprehensive review of microbial communities especially <em>F. nucleatum</em> in tumor tissue, exploring their roles and underlying mechanisms in tumor development, treatment, and prevention. When the tumor-associated <em>F. nucleatum</em> is killed, the host immune response is activated to recognize tumor cells. Bacteria epitopes restricted by the host antigens, can be identified for future anti-bacteria/tumor vaccine development.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115319"},"PeriodicalIF":16.1,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140786371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines","authors":"Laura Trujillo Cubillo,&nbsp;Mehmet Gurdal,&nbsp;Dimitrios I. Zeugolis","doi":"10.1016/j.addr.2024.115317","DOIUrl":"https://doi.org/10.1016/j.addr.2024.115317","url":null,"abstract":"<div><p>Fibrotic diseases are characterised by myofibroblast differentiation, uncontrolled pathological extracellular matrix accumulation, tissue contraction, scar formation and, ultimately tissue / organ dysfunction. The cornea, the transparent tissue located on the anterior chamber of the eye, is extremely susceptible to fibrotic diseases, which cause loss of corneal transparency and are often associated with blindness. Although topical corticosteroids and antimetabolites are extensively used in the management of corneal fibrosis, they are associated with glaucoma, cataract formation, corneoscleral melting and infection, imposing the need of far more effective therapies. Herein, we summarise and discuss shortfalls and recent advances in <em>in vitro</em> models (e.g. transforming growth factor-β (TGF-β) / ascorbic acid / interleukin (IL) induced) and drug (e.g. TGF-β inhibitors, epigenetic modulators) and gene (e.g. gene editing, gene silencing) therapeutic strategies in the corneal fibrosis context. Emerging therapeutical agents (e.g. neutralising antibodies, ligand traps, receptor kinase inhibitors, antisense oligonucleotides) that have shown promise in clinical setting but have not yet assessed in corneal fibrosis context are also discussed.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115317"},"PeriodicalIF":16.1,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X2400139X/pdfft?md5=0ce136cdcb2a3cf2c53c0cdcd4da753c&pid=1-s2.0-S0169409X2400139X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140633351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade","authors":"Youngjin Choi ,&nbsp;Su Hyun Seok ,&nbsp;Hong Yeol Yoon ,&nbsp;Ju Hee Ryu ,&nbsp;Ick Chan Kwon","doi":"10.1016/j.addr.2024.115306","DOIUrl":"10.1016/j.addr.2024.115306","url":null,"abstract":"<div><p>Cancer immunotherapy represents a revolutionary strategy, leveraging the patient's immune system to inhibit tumor growth and alleviate the immunosuppressive effects of the tumor microenvironment (TME). The recent emergence of immune checkpoint blockade (ICB) therapies, particularly following the first approval of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors like ipilimumab, has led to significant growth in cancer immunotherapy. The extensive explorations on diverse immune checkpoint antibodies have broadened the therapeutic scope for various malignancies. However, the clinical response to these antibody-based ICB therapies remains limited, with less than 15% responsiveness and notable adverse effects in some patients. This review introduces the emerging strategies to overcome current limitations of antibody-based ICB therapies, mainly focusing on the development of small interfering ribonucleic acid (siRNA)-based ICB therapies and innovative delivery systems. We firstly highlight the diverse target immune checkpoint genes for siRNA-based ICB therapies, incorporating silencing of multiple genes to boost anti-tumor immune responses. Subsequently, we discuss improvements in siRNA delivery systems, enhanced by various nanocarriers, aimed at overcoming siRNA's clinical challenges such as vulnerability to enzymatic degradation, inadequate pharmacokinetics, and possible unintended target interactions. Additionally, the review presents various combination therapies that integrate chemotherapy, phototherapy, stimulatory checkpoints, ICB antibodies, and cancer vaccines. The important point is that when used in combination with siRNA-based ICB therapy, the synergistic effect of traditional therapies is strengthened, improving host immune surveillance and therapeutic outcomes. Conclusively, we discuss the insights into innovative and effective cancer immunotherapeutic strategies based on RNA interference (RNAi) technology utilizing siRNA and nanocarriers as a novel approach in ICB cancer immunotherapy.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115306"},"PeriodicalIF":16.1,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24001285/pdfft?md5=0c29eec6a7b380dd14ecfdb8192cba05&pid=1-s2.0-S0169409X24001285-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140640585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines","authors":"Namratha Turuvekere Vittala Murthy ,&nbsp;Kseniia Vlasova ,&nbsp;Jonas Renner ,&nbsp;Antony Jozic ,&nbsp;Gaurav Sahay","doi":"10.1016/j.addr.2024.115305","DOIUrl":"https://doi.org/10.1016/j.addr.2024.115305","url":null,"abstract":"<div><p>Cystic fibrosis (CF) is a complex genetic respiratory disorder that necessitates innovative gene delivery strategies to address the mutations in the gene. This review delves into the promises and challenges of non-viral gene delivery for CF therapy and explores strategies to overcome these hurdles. Several emerging technologies and nucleic acid cargos for CF gene therapy are discussed. Novel formulation approaches including lipid and polymeric nanoparticles promise enhanced delivery through the CF mucus barrier, augmenting the potential of non-viral strategies. Additionally, safety considerations and regulatory perspectives play a crucial role in navigating the path toward clinical translation of gene therapy.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115305"},"PeriodicalIF":16.1,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140605447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interactions between nanoparticles and lymphatic systems: Mechanisms and applications in drug delivery","authors":"Yisi Tang ,&nbsp;Bao Liu ,&nbsp;Yuting Zhang ,&nbsp;Yuling Liu ,&nbsp;Yongzhuo Huang ,&nbsp;Wufa Fan","doi":"10.1016/j.addr.2024.115304","DOIUrl":"10.1016/j.addr.2024.115304","url":null,"abstract":"<div><p>The lymphatic system has garnered significant attention in drug delivery research due to the advantages it offers, such as enhancing systemic exposure and enabling lymph node targeting for nanomedicines via the lymphatic delivery route. The journey of drug carriers involves transport from the administration site to the lymphatic vessels, traversing the lymph before entering the bloodstream or targeting specific lymph nodes. However, the anatomical and physiological barriers of the lymphatic system play a pivotal role in influencing the behavior and efficiency of carriers. To expedite research and subsequent clinical translation, this review begins by introducing the composition and classification of the lymphatic system. Subsequently, we explore the routes and mechanisms through which nanoparticles enter lymphatic vessels and lymph nodes. The review further delves into the interactions between nanomedicine and body fluids at the administration site or within lymphatic vessels. Finally, we provide a comprehensive overview of recent advancements in lymphatic delivery systems, addressing the challenges and opportunities inherent in current systems for delivering macromolecules and vaccines.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115304"},"PeriodicalIF":16.1,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140542240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications","authors":"Jacob D. Bonadio,&nbsp;Ghazal Bashiri,&nbsp;Patrick Halligan,&nbsp;Michael Kegel,&nbsp;Fatima Ahmed,&nbsp;Karin Wang","doi":"10.1016/j.addr.2024.115303","DOIUrl":"https://doi.org/10.1016/j.addr.2024.115303","url":null,"abstract":"<div><p>Fibronectin (FN) is a critical component of the extracellular matrix (ECM) contributing to various physiological processes, including tissue repair and immune response regulation. FN regulates various cellular functions such as adhesion, proliferation, migration, differentiation, and cytokine release. Alterations in FN expression, deposition, and molecular structure can profoundly impact its interaction with other ECM proteins, growth factors, cells, and associated signaling pathways, thus influencing the progress of diseases such as fibrosis and autoimmune disorders. Therefore, developing therapeutics that directly target FN or its interaction with cells and other ECM components can be an intriguing approach to address autoimmune and fibrosis pathogenesis.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115303"},"PeriodicalIF":16.1,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140649560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics","authors":"Paula Gil-Cabrerizo ,&nbsp;Teresa Simon-Yarza ,&nbsp;Elisa Garbayo ,&nbsp;María J. Blanco Prieto","doi":"10.1016/j.addr.2024.115302","DOIUrl":"https://doi.org/10.1016/j.addr.2024.115302","url":null,"abstract":"<div><p>Cardiovascular diseases (CVDs) stand as the leading cause of death worldwide, posing a significant global health challenge. Consequently, the development of innovative therapeutic strategies to enhance CVDs treatment is imperative. RNA-based therapies, encompassing non-coding RNAs, mRNA, aptamers, and CRISPR/Cas9 technology, have emerged as promising tools for addressing CVDs. However, inherent challenges associated with RNA, such as poor cellular uptake, susceptibility to RNase degradation, and capture by the reticuloendothelial system, underscore the necessity of combining these therapies with effective drug delivery systems.</p><p>Various non-viral delivery systems, including extracellular vesicles, lipid-based carriers, polymeric and inorganic nanoparticles, as well as hydrogels, have shown promise in enhancing the efficacy of RNA therapeutics. In this review, we offer an overview of the most relevant RNA-based therapeutic strategies explored for addressing CVDs and emphasize the pivotal role of delivery systems in augmenting their effectiveness. Additionally, we discuss the current status of these therapies and the challenges that hinder their clinical translation.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"208 ","pages":"Article 115302"},"PeriodicalIF":16.1,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24001248/pdfft?md5=b7d72182b1c54ed96276ba384add1421&pid=1-s2.0-S0169409X24001248-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140533311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design","authors":"Neil Mathias ,&nbsp;Sylvain Huille ,&nbsp;Marie Picci ,&nbsp;Robert P. Mahoney ,&nbsp;Ronald J. Pettis ,&nbsp;Brian Case ,&nbsp;Bernhard Helk ,&nbsp;David Kang ,&nbsp;Ronak Shah ,&nbsp;Junchi Ma ,&nbsp;Deep Bhattacharya ,&nbsp;Yogita Krishnamachari ,&nbsp;Dany Doucet ,&nbsp;Nathalie Maksimovikj ,&nbsp;Sahab Babaee ,&nbsp;Patrick Garidel ,&nbsp;Reza Esfandiary ,&nbsp;Rajesh Gandhi","doi":"10.1016/j.addr.2024.115301","DOIUrl":"https://doi.org/10.1016/j.addr.2024.115301","url":null,"abstract":"<div><p>Subcutaneous (SC) injections can be associated with local pain and discomfort that is subjective and may affect treatment adherence and overall patient experience. With innovations increasingly focused on finding ways to deliver higher doses and volumes (≥2 mL), there is a need to better understand the multiple intertwined factors that influence pain upon SC injection. As a priority for the SC Drug Development &amp; Delivery Consortium, this manuscript provides a comprehensive review of known attributes from published literature that contribute to pain/discomfort upon SC injection from three perspectives: (1) device and delivery factors that cause physical pain, (2) formulation factors that trigger pain responses, and (3) human factors impacting pain perception. Leveraging the Consortium’s collective expertise, we provide an assessment of the comparative and interdependent factors likely to impact SC injection pain. In addition, we offer expert insights and future perspectives to fill identified gaps in knowledge to help advance the development of patient-centric and well tolerated high-dose/high-volume SC drug delivery solutions.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115301"},"PeriodicalIF":16.1,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140639372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}